Symbol="RETA"
AssetType="Common Stock"
Name="Reata Pharmaceuticals Inc"
Description="Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapies for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cell metabolism and inflammation. The company is headquartered in Plano, Texas."
CIK="1358762"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="5320 LEGACY DRIVE, PLANO, TX, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="6436539000"
EBITDA="-340537984"
PERatio="None"
PEGRatio="0"
BookValue="2.306"
DividendPerShare="0"
DividendYield="0"
EPS="-2.6"
RevenuePerShareTTM="0.635"
ProfitMargin="0"
OperatingMarginTTM="-14.55"
ReturnOnAssetsTTM="-0.377"
ReturnOnEquityTTM="-1.124"
RevenueTTM="23480000"
GrossProfitTTM="-167627000"
DilutedEPSTTM="-2.6"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="28.85"
AnalystTargetPrice="172.45"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="414.73"
PriceToBookRatio="285.94"
EVToRevenue="316.34"
EVToEBITDA="-3.746"
Beta="1.437"
num_52WeekHigh="169.75"
num_52WeekLow="21.83"
num_50DayMovingAverage="131.95"
num_200DayMovingAverage="82.45"
SharesOutstanding="33587600"
DividendDate="None"
ExDividendDate="None"
symbol="RETA"
open="169.19"
high="169.20"
low="168.80"
price="168.88"
volume="624799.00"
latest_trading_day="2023-08-29"
previous_close="168.90"
change="-0.02"
change_percent="-0.0118%"
aroon_positive_momentum_days="73"
aroon_negative_momentum_days="0"
trend_strength="Strong Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Overbought"
value_analysis="Overvalued"
Aroon_change="FALSE"
Aroon_momentum="73"
Volume_recent_avg="896328"
Change_recent_avg="0.13"
Delta_recent_avg="3.59"
Variance_recent_avg="1.8"
Change_ratio_recent_avg="0.08"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="73"
Aroon_momentum_negative="27"
image_negative_thumbnail_id_1="488"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0117.jpeg"
image_negative_thumbnail_id_2="1160"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0194.jpeg"
image_neutral_thumbnail_id_1="590"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0009.jpeg"
image_neutral_thumbnail_id_2="523"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0076.jpeg"
image_positive_thumbnail_id_1="662"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0046.jpeg"
image_positive_thumbnail_id_2="641"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0067.jpeg"
image_professor_thumbnail_id_1="1200"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0034.jpeg"
image_professor_thumbnail_id_2="1191"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0025.jpeg"
